MX2020004792A - Formulaciones de fulvestrant y metodos de su uso. - Google Patents

Formulaciones de fulvestrant y metodos de su uso.

Info

Publication number
MX2020004792A
MX2020004792A MX2020004792A MX2020004792A MX2020004792A MX 2020004792 A MX2020004792 A MX 2020004792A MX 2020004792 A MX2020004792 A MX 2020004792A MX 2020004792 A MX2020004792 A MX 2020004792A MX 2020004792 A MX2020004792 A MX 2020004792A
Authority
MX
Mexico
Prior art keywords
microns
alkyl
methods
soluble excipient
water
Prior art date
Application number
MX2020004792A
Other languages
English (en)
Inventor
Rama Abu Shmeis
Michael Joyce
Feng- Jing Chen
Steven L Krill
Adrian Hepner
Charles Wescott
Tara Jaskowski
Original Assignee
Eagle Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64650494&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2020004792(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eagle Pharmaceuticals Inc filed Critical Eagle Pharmaceuticals Inc
Publication of MX2020004792A publication Critical patent/MX2020004792A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente descripción proporciona métodos de tratamiento del cáncer de mama que incluyen la administración de suspensiones acuosas que comprenden fulvestrant solubilizado, partículas de fulvestrant no solubilizadas que tienen uno o más de un LD Dv(10) entre aproximadamente 1.5 y aproximadamente 2.1 micrómetros, un LD Dv(50) entre aproximadamente 5.5 y aproximadamente 9.0 micrómetros y un LD (Dv) entre aproximadamente y aproximadamente 35 micrómetros, con la suspensión acuosa incluyendo además un tensoactivo, una polivinilpirrolidona y un alcohol de azúcar y un excipiente soluble en agua. El excipiente soluble en agua puede ser un aril-alquil de C1-6-OH un alquil de C1-6-OH, una sal amortiguadora, un polisorbato, un polialquilenglicol, un alquilenglicol de C1-12, una fosfatidilcolina o una combinación de los mismos.
MX2020004792A 2017-11-08 2018-11-08 Formulaciones de fulvestrant y metodos de su uso. MX2020004792A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762583403P 2017-11-08 2017-11-08
PCT/US2018/059906 WO2019094650A1 (en) 2017-11-08 2018-11-08 Fulvestrant formulations and methods of their use

Publications (1)

Publication Number Publication Date
MX2020004792A true MX2020004792A (es) 2020-08-13

Family

ID=64650494

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020004792A MX2020004792A (es) 2017-11-08 2018-11-08 Formulaciones de fulvestrant y metodos de su uso.
MX2024010323A MX2024010323A (es) 2017-11-08 2020-07-13 Formulaciones de fulvestrant y metodos de su uso

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024010323A MX2024010323A (es) 2017-11-08 2020-07-13 Formulaciones de fulvestrant y metodos de su uso

Country Status (16)

Country Link
US (1) US12186427B2 (es)
EP (1) EP3706719A1 (es)
JP (1) JP7220712B2 (es)
KR (1) KR102670293B1 (es)
CN (1) CN111479556B (es)
AU (1) AU2018366212B2 (es)
BR (1) BR112020009141A2 (es)
CA (1) CA3082193A1 (es)
CO (1) CO2020006951A2 (es)
IL (1) IL274433B2 (es)
MA (1) MA50570A (es)
MX (2) MX2020004792A (es)
MY (1) MY204442A (es)
UA (1) UA128158C2 (es)
WO (1) WO2019094650A1 (es)
ZA (1) ZA202002897B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12377049B2 (en) * 2019-12-11 2025-08-05 Shanghai Bocimed Pharmaceutical Co., Ltd. Fulvestrant pharmaceutical composition, preparation method therefor, and application thereof
CN120284882A (zh) * 2020-12-10 2025-07-11 上海云晟研新生物科技有限公司 氟维司群药物组合物、其制备方法及应用
JP2024545690A (ja) * 2021-12-20 2024-12-10 サムヤン、ホールディングス、コーポレーション 溶解度が改善されたフルベストラントの医薬組成物及びその製造方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
US6495534B2 (en) * 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use
IL159576A0 (en) 2001-07-07 2004-06-01 Astrazeneca Ab Pharmaceutical formulation for the intramuscular administration of fulvestrant
WO2006013369A2 (en) 2004-08-04 2006-02-09 Camurus Ab Compositions forming non-lamellar dispersions
JP2006089386A (ja) * 2004-09-21 2006-04-06 Nippon Tenganyaku Kenkyusho:Kk ステロイドまたはステロイド誘導体を含有する懸濁性医薬組成物
CN1857217A (zh) * 2006-03-28 2006-11-08 济南康泉医药科技有限公司 一种含雌激素受体拮抗剂的抗癌缓释注射剂
CN101244029A (zh) * 2006-03-28 2008-08-20 济南康泉医药科技有限公司 含雌激素受体拮抗剂的抗癌缓释注射剂
CN102014925B (zh) * 2008-03-07 2013-02-06 赛多斯有限责任公司 氟维司群配制剂
CN101525364B (zh) 2008-03-07 2012-12-12 杭州九源基因工程有限公司 一种氟维司群的晶型及其制备方法
EP2460539A4 (en) * 2009-07-31 2013-12-04 Xi An Libang Medical Technology Co Ltd MEDICAMENT IN THE FORM OF NANO OR MICROBALLS, METHOD FOR THE PRODUCTION THEREOF AND COMPOSITION THEREOF AND USE THEREOF
WO2011022861A1 (zh) 2009-08-31 2011-03-03 西安力邦医药科技有限责任公司 氟维司群纳米球/微球及其制备方法和用途
EA201300341A1 (ru) * 2010-09-16 2013-09-30 Шимода Байотек (Пти) Лтд. Композиция фулвестранта и способы применения
US9029582B2 (en) 2011-05-20 2015-05-12 Capital, Business Y Gestion De Finanzas S.L. Pharmaceutical composition
WO2013153559A1 (en) 2012-04-09 2013-10-17 Scidose, Llc Fulvestrant formulations
SG10201706196XA (en) 2012-06-08 2017-08-30 Hoffmann La Roche Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
CN104782169B (zh) * 2013-07-08 2019-06-28 华为技术有限公司 视频播放的控制方法、设备及系统
CN104337761B (zh) * 2013-08-07 2019-03-26 江苏豪森药业集团有限公司 氟维司群药物组合物
JP2016529308A (ja) * 2013-09-06 2016-09-23 サラー ウッディン アハメド， フルベストラント組成物
US11590077B2 (en) * 2016-05-06 2023-02-28 Eagle Pharmaceuticals, Inc. Fulvestrant formulations and methods of their use
IL285928B2 (en) 2016-05-06 2025-06-01 Eagle Pharmaceuticals Inc Fulvestrant formulations and methods of their use

Also Published As

Publication number Publication date
MA50570A (fr) 2020-09-16
CN111479556B (zh) 2023-09-01
US20230404918A1 (en) 2023-12-21
CN111479556A (zh) 2020-07-31
RU2020118559A (ru) 2021-12-08
JP2021502362A (ja) 2021-01-28
ZA202002897B (en) 2023-10-25
BR112020009141A2 (pt) 2020-10-27
CA3082193A1 (en) 2019-05-16
RU2020118559A3 (es) 2021-12-08
JP7220712B2 (ja) 2023-02-10
KR102670293B1 (ko) 2024-05-30
WO2019094650A1 (en) 2019-05-16
EP3706719A1 (en) 2020-09-16
MY204442A (en) 2024-08-28
US12186427B2 (en) 2025-01-07
CO2020006951A2 (es) 2020-06-19
KR20200085809A (ko) 2020-07-15
AU2018366212A1 (en) 2020-05-14
IL274433B1 (en) 2024-03-01
AU2018366212B2 (en) 2024-06-20
UA128158C2 (uk) 2024-04-24
MX2024010323A (es) 2025-02-10
IL274433B2 (en) 2024-07-01
IL274433A (en) 2020-06-30

Similar Documents

Publication Publication Date Title
CO2020006951A2 (es) Formulaciones de fulvestrant y métodos de su uso
MX2015013894A (es) Composiciones de nanoparticulas novedosas.
MX2017000578A (es) Tratamiento de cancer con una combinacion de radiacion, nanoparticulas de oxido de cerio y un agente quimioterapeutico.
MX2018009298A (es) Bomba de sistema de diálisis con conector.
CL2019001366A1 (es) Formulaciones tamponadas exendina (9-39).
MX391135B (es) Terapias de combinacion.
AR100334A1 (es) Solución oftálmica acuosa y método para tratar el síndrome del ojo seco
MX360254B (es) Combinacion de terapias inmunomoduladoras local y sistemica para tratamiento mejorado del cancer.
MX2017000609A (es) Dispositivo y metodo de entrega de implante ocular.
MX2018007933A (es) Metodo de tratamiento de mamifero, incluido el ser humano, contra cancer usando agotamiento de metionina y asparagina.
CO2020000328A2 (es) Formulaciones a largo plazo
MX2015012783A (es) Administracion subcutanea de una desintegrina y metaloproteinasa con motivos tipo i de trombospondina 13 (adamts13).
MX2020011712A (es) Vacunas de nanoparticulas multivalentes contra la influenza.
MX2020005357A (es) Composiciones para el cuidado oral.
MX2017006812A (es) Composición farmacéutica, preparación y usos de la misma.
MX2016015211A (es) Formulaciones topicas y usos de las mismas.
MX2019008656A (es) Composiciones farmaceuticas nasales para reducir los riesgos de la exposicion a los contaminantes del aire.
AR092691A1 (es) Composicion farmaceutica que comprende rebamipida
AR102778A1 (es) Composición farmacéutica, su preparación y sus usos
AR099751A1 (es) Formulaciones basadas en melatonina para administración parenteral
MX2019000444A (es) Articulo absorbente con aletas de contencion de materia fecal mejoradas.
CU24650B1 (es) Combinaciones que incluyen abx196 útiles en el tratamiento del cáncer
ES2811674R1 (es) Compuestos de ácido ascórbico y quinona en combinación con un agente antiparasitario para el tratamiento de una enfermedad parasitaria
MX2020008699A (es) Gotas para los ojos en forma de solucion que comprende un derivado de benzopirano o una sal farmaceuticamente aceptable del mismo.
CL2015002898A1 (es) Dispositivo de tracción para vagón de ferrocarril, que comprende un alojamiento que tiene una cavidad interna, un extremo frontal con una abertura, bordes de soporte integrales, nervaduras centrales y una cuña de fricción dentro de la cavidad del alojamiento, con una zapata en la superficie exterior y un cojinete en contacto.